Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

被引:14
|
作者
Milic, Jovana [1 ,2 ]
Menozzi, Valentina [3 ]
Schepis, Filippo [4 ]
Malagoli, Andrea [1 ]
Besutti, Giulia [2 ]
Franconi, Iacopo [1 ]
Raimondi, Alessandro [1 ]
Carli, Federica [1 ]
Mussini, Cristina [1 ]
Sebastiani, Giada [5 ]
Guaraldi, Giovanni [1 ]
机构
[1] Univ Modena & Reggio Emilia, Modena HIV Metab Clin, Modena, Italy
[2] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Modena & Reggio Emilia, Dept Gastroenterol, Modena, Italy
[5] McGill Univ, Dept Med, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
frailty; HIV; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; METABOLIC SYNDROME; STEATOHEPATITIS; MANAGEMENT; DIAGNOSIS; OBESITY; NAFLD;
D O I
10.1097/QAD.0000000000002650
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019. Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP >= 248 dB/m), while significant liver fibrosis or cirrhosis (stage >= F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4(+) cell count 700 cells/mu l, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4). Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH. Copyright (C) 2020 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1915 / 1921
页数:7
相关论文
共 50 条
  • [31] Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease
    Karakousis, Nikolaos D.
    Chrysavgis, Lampros
    Chatzigeorgiou, Antonios
    Papatheodoridis, George
    Cholongitas, Evangelos
    ANNALS OF GASTROENTEROLOGY, 2022, 35 (03): : 234 - 242
  • [32] Molecular mechanisms of steatosis in nonalcoholic fatty liver disease
    Pettinelli, P.
    Obregon, A. M.
    Videla, L. A.
    NUTRICION HOSPITALARIA, 2011, 26 (03) : 441 - 450
  • [33] Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease
    Dogan, Serkan
    Celikbilek, Mehmet
    Yilmaz, Yunus K.
    Sarikaya, Savas
    Zararsiz, Gokmen
    Serin, Halil I.
    Borekci, Elif
    Akyol, Lutfi
    Pirti, Ilyas
    Davarci, Sena E.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (03) : 298 - 304
  • [34] Dietary intake of patients with Nonalcoholic Fatty Liver Disease: Comparison between the presence and absence of Nonalcoholic Steatosis and Metabolic Syndrome
    Sena Crispim, Fany Govetri
    Elias, Maria Cristina
    Parise, Edison Roberto
    REVISTA DE NUTRICAO-BRAZILIAN JOURNAL OF NUTRITION, 2016, 29 (04): : 495 - 505
  • [35] Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis
    Tilg, Herbert
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) : 1893 - 1895
  • [36] Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
    Lefere, Sander
    Dupont, Ellen
    De Guchtenaere, Ann
    Van Biervliet, Stephanie
    Vande Velde, Saskia
    Verhelst, Xavier
    Devisscher, Lindsey
    Van Vlierberghe, Hans
    Geerts, Anja
    De Bruyne, Ruth
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) : 2317 - +
  • [37] Sex hormone binding globulin (SHBG) as a predictor of liver fibrosis in subjects with nonalcoholic fatty liver disease (NAFLD)
    Abdel-latif, Abeer
    Al-Jarhi, Ula Mabid
    Hesham, Dina
    Khozam, Mona
    Fathy, Shaimaa A.
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2023, 35 (01)
  • [38] Epigenetics factors in nonalcoholic fatty liver disease
    Pirola, Carlos Jose
    Sookoian, Silvia
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (06) : 521 - 536
  • [39] Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease
    Chen, Ying
    Xu, Min
    Wang, Tiange
    Sun, Jichao
    Sun, Wanwan
    Xu, Baihui
    Huang, Xiaolin
    Xu, Yu
    Lu, Jieli
    Li, Xiaoying
    Wang, Weiqing
    Bi, Yufang
    Ning, Guang
    ATHEROSCLEROSIS, 2015, 241 (01) : 145 - 150
  • [40] In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis
    Africa, Jonathan A.
    Behling, Cynthia A.
    Brunt, Elizabeth M.
    Zhang, Nan
    Luo, Yunjun
    Wells, Alan
    Hou, Jiayi
    Belt, Patricia H.
    Kohil, Rohit
    Lavine, Joel E.
    Molleston, Jean P.
    Newton, Kimberly P.
    Whitington, Peter F.
    Schwimmer, Jeffrey B.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (03) : 438 - +